Liquidia Corporation
LQDA
Classement en actions
#4411
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating... Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Prix de l'action
$38.75
Dernière synchronisation: 2026-10-21
Capitalisation boursière
$3.47B
Changement (1 jour)
6.60%
Changement (1 an)
73.46%
Pays
US
Échange Liquidia Corporation (LQDA)
Catégorie
Healthcare
Historique du prix de l'action pour Liquidia Corporation (LQDA)
Prix de clôture le plus élevé : $30.60 le 2026-10-01
Prix de clôture le plus bas : $11.01 le 2018-07-01
Prix de clôture le plus bas : $11.01 le 2018-07-01
Historique du prix de l'action de Liquidia Corporation de 2018 à 2026
Performance annuelle du prix de l'action
| Année | Performance |
|---|---|
| 2026 (TTM) | 42.98% |
| 2025 | 204.28% |
| 2024 | 26.82% |
| 2023 | 47.93% |
| 2022 | 37.03% |
| 2021 | 48.32% |
| 2020 | -24.23% |
| 2019 | -82.68% |
| 2018 | 0.00% |
Prix de l'action pour des entreprises similaires ou concurrentes
| Entreprise | Prix de l'action | Variation 1a% | Pays |
|---|---|---|---|
| $62.20 | 68.82% |
US
|
|
| $45.44 | 35.30% |
SE
|
|
| $171.04 | 23.67% |
FR
|
|
| $116.39 | 58.03% |
US
|
|
| $59.52 | -0.48% |
IT
|
